Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the ext...
Main Authors: | Giuseppe Privitera, Daniela Pugliese, Loris Riccardo Lopetuso, Franco Scaldaferri, Matteo Neri, Luisa Guidi, Antonio Gasbarrini, Alessandro Armuzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-04-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/17562848211006669 |
Similar Items
-
Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
by: Giuseppe Privitera, et al.
Published: (2021-02-01) -
The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
by: Grainne Holleran, et al.
Published: (2017-09-01) -
Update on the management of inflammatory bowel disease: specific role of adalimumab
by: Guidi L, et al.
Published: (2011-07-01) -
Frontiers in Drug Research and Development for Inflammatory Bowel Disease
by: Diego Currò, et al.
Published: (2017-06-01) -
Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase
by: Alfredo Papa, et al.
Published: (2020-10-01)